Evidence map›Paper›PMID 28558813›Full record

ReviewGenome medicine2017

Genome annotation for clinical genomic diagnostics: strengths and weaknesses.

Charles A Steward, Alasdair P J Parker, Berge A Minassian, Sanjay M Sisodiya, Adam Frankish, Jennifer Harrow

Abstract readReview
In one paragraph

Review in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. A Pathogenic Variant Reclassified to the PseudogeneInternational journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The future of cystic fibrosis care: a global perspective.The Lancet. Respiratory medicine · 2020
    Review
  19. Chromosome-Level Alpaca Reference GenomeFrontiers in genetics · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charles A StewardCongenica Ltd, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK. charles.steward@congenica.com.
Alasdair P J ParkerAddenbrooke's Hospital and University of Cambridge, Cambridge, CB2 0QQ, UK.
Berge A MinassianDepartment of Pediatrics (Neurology), University of Texas Southwestern, Dallas, TX, USA.
Sanjay M SisodiyaDepartment of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, WC1N 3BG, UK.
Adam FrankishThe Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Jennifer HarrowThe Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

Funding

GENCODE Resource ProjectU41HG007234 · NHGRI · SANGER INSTITUTE · PI FLICEK, PAUL · 2013 to 2020
$20.3M
NHGRI NIH HHS U41 HG007234Wellcome Trust
6 · The paper itself

Abstract

The Human Genome Project and advances in DNA sequencing technologies have revolutionized the identification of genetic disorders through the use of clinical exome sequencing. However, in a considerable number of patients, the genetic basis remains unclear. As clinicians begin to consider whole-genome sequencing, an understanding of the processes and tools involved and the factors to consider in the annotation of the structure and function of genomic elements that might influence variant identification is crucial. Here, we discuss and illustrate the strengths and weaknesses of approaches for the annotation and classification of important elements of protein-coding genes, other genomic elements such as pseudogenes and the non-coding genome, comparative-genomic approaches for inferring gene function, and new technologies for aiding genome annotation, as a practical guide for clinicians when considering pathogenic sequence variation. Complete and accurate annotation of structure and function of genome features has the potential to reduce both false-negative (from missing annotation) and false-positive (from incorrect annotation) errors in causal variant identification in exome and genome sequences. Re-analysis of unsolved cases will be necessary as newer technology improves genome annotation, potentially improving the rate of diagnosis.

Indexed as

Diagnostic Techniques and ProceduresGenetic VariationHumansMolecular Sequence AnnotationPseudogenesSequence Analysis, DNA

Identifiers

PMID28558813
PMCPMC5448149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.